---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-117193"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:03:55.601668+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Liquidia Q3 net loss $23.2M; FDA tentative approval for YUTREPIA; raised $100M

## Summary
- Net loss of $23.2M ($0.30/diluted share) vs $15.8M loss a year ago; revenue $4.4M from Treprostinil injection promotion.
- Cash $204.4M as of Sep 30, 2024, boosted by $67.5M public offering and $32.5M from HCRx RIFA amendment.
- FDA granted tentative approval for YUTREPIA (treprostinil inhalation powder) for PAH and PH-ILD; final approval delayed until May 23, 2025.
- Supreme Court rejected UTHR appeal on '793 patent; remaining '327 patent trial set for June 2025; Liquidia sued FDA over exclusivity.
- Expanded Pharmosa collaboration for L606 to Europe, Japan; $3.5M upfront, up to $157.75M milestones.

## SEC filing metadata
- accession: 0001104659-24-117193
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465924117193/0001104659-24-117193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465924117193/tm2428261d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-117193
- JSON: https://secwatch.observer/filing/0001104659-24-117193.json
- Plain text: https://secwatch.observer/filing/0001104659-24-117193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.